You are here: Industry Insights > lung cancer

News List

FDA approves expanded use of Novartis’ lung cancer drug Zykadia europeanpharmaceuticalreview
May 31, 2017
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’ Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)...
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial worldpharmanews
May 15, 2017
AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded...
AstraZeneca’s lung cancer drug receives full approval in the EU europeanpharmaceuticalreview
April 28, 2017
The European Commission (EC) has granted full marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-smal
Roche’s Alecensa beats Pfizer’s Xalkori in lung cancer trial pharmatimes
April 11, 2017
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free ...
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer worldpharmanews
April 11, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global, randomised phase III ALEX study met its primary endpoint and showed that Alecensa® (alectinib)
Genentech’s Alecensa superior to crizotinib in certain Lung Cancer: study biospectrumasia
April 11, 2017
Alecensa was granted accelerated approval by the FDA in December 2015 for the treatment of people with ALK-positive NSCLC
AstraZeneca lung cancer drug receives FDA approval europeanpharmaceuticalreview
April 05, 2017
The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets...
Antioxidants and lung cancer risk worldpharmanews
March 09, 2017
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
NICE does not recommend Merck’s lung cancer drug pharmaasia
March 03, 2017
The National Institute for Health and Care Excellence (NICE) has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer.
CR UK, HitGen work together on new lung cancer medicines pharmatimes
March 02, 2017
Cancer Research UK, its commercial arm Cancer Research Technology (CRT) and private biotech HitGen have entered into ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page